🟢 Citius Pharmaceuticals is trading 5% up in pre-market

Citius Pharmaceuticals is trading at $0.49, up +5.42%, with no verified company-specific news explaining the pre-market rise.

• The latest company announcement found was an October 12 notice about investor conferences, including a presentation scheduled for October 15.
• October 14 coverage reported an FDA Complete Response Letter for LYMPHIR, citing enhanced product-testing requirements—not an approval. That adverse news does not explain the rise.
• Broader markets were weak, so the move does not appear aligned with the supplied market direction.